Fill out the form below to get your free eBook!
Upcoming Event
Long COVID Clinical Trial
The Beljanski Foundation is sponsoring a new clinical trial for patients with Long COVID because of the urgent need for a new and successful treatment. Anecdotal reports from patients experiencing lingering symptoms from an infection with SARS-CoV-2 started to emerge shortly after the beginning of the pandemic, and the term “Long COVID” was coined to name this condition and alert the scientific community. Upwards of 65 million people worldwide are now suffering from this condition. The goal is to test whether the administration of a special preparation of small RNA fragments, originally developed by Dr. Mirko Beljanski, will work by stimulating stem cells in the bone marrow to produce new immune cells. Previous research conducted on this special preparation at Cancer Treatment Centers of America confirmed its safety and effectiveness for treating thrombocytopenia (low platelets) caused by chemotherapy. Thrombocytopenia has been seen in a significant number of Long COVID patients, and low platelets are associated with fatigue – a major symptom of Long COVID. The trial will also reveal the potential of the RNA fragments to re-balance immunity in these patients.
Support Long COVID Research
While the critical role of RNA primers was first discovered by Okazaki, those short segments of RNA acting as primers for initiating the synthesis of new strands of DNA were originally developed by Dr. Beljanski, a French Biologist from the Pasteur Institute in Paris, France. The fragments work by stimulating stem cells in the bone marrow to produce our immune cells. They have been available as dietary ingredients in the US since the 90s, and it is a commercial preparation made available by Maison Beljanski, which will be used for the clinical trial. Enrollment for the clinical trial is already on its way in Europe. The findings are expected to provide valuable insight into whether improving bone marrow function and patient immunity is a pathway for successful Long COVID treatment.
“Platelet levels have been measured in depressed patients and have been found to be decreased when compared to normal controls. Therefore, interference in this process might be a promising avenue for further research to address mild thrombocytopenia in people with Long COVID, along with the most common side effects of this condition, which are fatigue and depression,” says Dr. John Hall, Director of Research at the Beljanski Foundation.
HEALTHY TUESDAY ABOUTVaccine Detoxification, Reducing Inflammation, and Support of the Immune SystemON DEMAND
Hear directly fromSylvie Beljanski and Dr. Michael Karlfeldt, ND, PhD
Every month at Healthy Tuesdays – virtual events organized to help you Feel Better Naturally – we feature healthcare professionals who come together to share information and advice related to holistic health.
This virtual Healthy Tuesday event featured keynote speakers Dr. Michael Karlfeldt, board-certified naturopath/integrative medicine specialist, and Sylvie Beljanski, Founder and Executive Vice President of The Beljanski Foundation, whose mission is to cure cancer the natural way. The two enlightened everyone with their insights and approach to vaccine detoxification, reducing inflammation, and supporting the immune system.
We invite you to watch the event recording on demand.
HEALTHY TUESDAY ABOUTVaccine Booster, Vaccine DetoxON DEMAND
Hear directly from Sylvie Beljanski
Every month at Healthy Tuesdays – virtual events organized to help you Feel Better Naturally – we feature healthcare professionals who come together to share information and advice related to holistic health.
This event featured the latest information on Vaccine Booster, Vaccine Detox. Sylvie Beljanski and a special guest speaker in integrative medicine, shared information and provided people with a unique perspective on the topic that they won’t find anywhere else!
We invite you to watch the event recording on demand.
Do you have a question? We are here to help you
The Beljanski Foundation team is at your disposal.
Share